Literature DB >> 26622415

High expression of microRNA-208 is associated with cardiac hypertrophy via the negative regulation of the sex-determining region Y-box 6 protein.

Xintao Huang1, Zhiheng Li2, Baoqiang Bai1, Xiaohong Li1, Zhongyuan Li1.   

Abstract

The aim of this study was to investigate the expression levels of microRNA-208 (miR-208) and sex-determining region Y-box 6 (SOX6) in patients with progressive cardiac hypertrophy. A total of 50 patients with essential hypertension accompanied by left ventricular hypertrophy, and 30 healthy individuals were enrolled. Peripheral blood samples were collected in order to compare miR-208 expression levels between the cardiac hypertrophy patients and healthy individuals. In addition, an in vitro cellular model of cardiac hypertrophy was established to determine the association between miR-208 and SOX6 expression. Rat cardiomyocytes were treated with phenylephrine (PE) to induce cardiac hypertrophy. Some of the hypertrophic cardiomyocytes were subsequently transfected with antagomiR-208, an miR-208 antagonist, in order to determine the effects of silencing miR-208 expression. Differences between healthy and hypertrophic cardiomyocyte morphology were evaluated using immunofluorescence staining. The mRNA expression levels of the hypertrophy-associated genes β-myosin heavy chain, α-sarcomeric actin and atrial natriuretic peptide were determined using quantitative polymerase chain reaction (qPCR). The mRNA and protein expression levels of miR-208 and SOX6 in peripheral blood and cardiomyocytes were detected using qPCR and western blot analysis, respectively. The expression levels of miR-208 were significantly increased in the peripheral blood of patients with left ventricular hypertrophy (P<0.05). PE-stimulated cardiomyocytes were significantly increased in size compared with normal cardiomyocytes. In the PE-stimulated cardiomyocytes, miR-208 expression levels were significantly increased (P<0.05). However, SOX6 expression levels were significantly decreased compared with those in normal cardiomyocytes (P<0.05). Following transfection with antagomiR-208, SOX6 expression levels in the PE-stimulated cardiomyocytes significantly increased, while the total mRNA and protein expression levels of hypertrophy-associated genes significantly decreased (P<0.05). miR-208 expression levels are increased in the peripheral blood of patients with cardiac hypertrophy. Therefore, the results of this study suggest that the expression levels of miR-208 are associated with cardiac hypertrophy by the negative regulation of SOX6.

Entities:  

Keywords:  cardiomyocytes; hypertrophy; microRNA-208; sex-determining region Y-box 6

Year:  2015        PMID: 26622415      PMCID: PMC4533156          DOI: 10.3892/etm.2015.2645

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  17 in total

1.  Identification of regulatory elements directing miR-23a-miR-27a-miR-24-2 transcriptional regulation in response to muscle hypertrophic stimuli.

Authors:  Francisco Hernandez-Torres; Amelia E Aranega; Diego Franco
Journal:  Biochim Biophys Acta       Date:  2014-07-19

2.  NF-κB (p65) negatively regulates myocardin-induced cardiomyocyte hypertrophy through multiple mechanisms.

Authors:  Xing-Hua Liao; Nan Wang; Dong-Wei Zhao; De-Liang Zheng; Li Zheng; Wen-Jing Xing; Hao Zhou; Dong-Sun Cao; Tong-Cun Zhang
Journal:  Cell Signal       Date:  2014-08-23       Impact factor: 4.315

3.  Positive feedback loop between Sox2 and Sox6 inhibits neuronal differentiation in the developing central nervous system.

Authors:  Kyung Eun Lee; Jihae Seo; Jiheon Shin; Eun Hye Ji; Jiwon Roh; Joo Yeon Kim; Woong Sun; Jonas Muhr; Sanghyuk Lee; Jaesang Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-05       Impact factor: 11.205

4.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans.

Authors:  Guo-Kun Wang; Jia-Qi Zhu; Jun-Tao Zhang; Qing Li; Yue Li; Jia He; Yong-Wen Qin; Qing Jing
Journal:  Eur Heart J       Date:  2010-02-16       Impact factor: 29.983

5.  Expression of Cx43-related microRNAs in patients with tetralogy of Fallot.

Authors:  Yao Wu; Xiao-Jing Ma; Hui-Jun Wang; Wen-Can Li; Long Chen; Duan Ma; Guo-Ying Huang
Journal:  World J Pediatr       Date:  2013-10-21       Impact factor: 2.764

6.  Ablation of plasma membrane Ca(2+)-ATPase isoform 4 prevents development of hypertrophy in a model of hypertrophic cardiomyopathy.

Authors:  Vikram Prasad; John N Lorenz; Valerie M Lasko; Michelle L Nieman; Min Jiang; Xu Gao; Jack Rubinstein; David F Wieczorek; Gary E Shull
Journal:  J Mol Cell Cardiol       Date:  2014-10-02       Impact factor: 5.000

7.  Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma.

Authors:  Heping Li; Dayong Zheng; Bing Zhang; Liangshuai Liu; Junwei Ou; Wei Chen; Shiqiu Xiong; Yong Gu; Jianyong Yang
Journal:  J Transl Med       Date:  2014-07-15       Impact factor: 5.531

8.  Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.

Authors:  Bianca C Bernardo; Xiao-Ming Gao; Yow Keat Tham; Helen Kiriazis; Catherine E Winbanks; Jenny Y Y Ooi; Esther J H Boey; Susanna Obad; Sakari Kauppinen; Paul Gregorevic; Xiao-Jun Du; Ruby C Y Lin; Julie R McMullen
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity.

Authors:  Jionghua Huang; Wen Sun; He Huang; Jing Ye; Wei Pan; Yun Zhong; Chuanfang Cheng; Xiangyu You; Benrong Liu; Longgen Xiong; Shiming Liu
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

10.  Kinetics of orthostatic blood pressure in primary hypertension.

Authors:  Fatima Zahra Milouk; Mustapha El Bakkali; Leslie Coghlan; Amal Lachhab; Souad Aboudrar; Halima Benjelloun
Journal:  Int Cardiovasc Res J       Date:  2014-09-01
View more
  6 in total

1.  Causal influences of neuroticism on mental health and cardiovascular disease.

Authors:  Fuquan Zhang; Ancha Baranova; Chao Zhou; Hongbao Cao; Jiu Chen; Xiangrong Zhang; Mingqing Xu
Journal:  Hum Genet       Date:  2021-05-11       Impact factor: 4.132

Review 2.  Sox6, A Potential Target for MicroRNAs in Cardiometabolic Disease.

Authors:  Mohammad Saleem; Sharla Rahman; Fernando Elijovich; Cheryl L Laffer; Lale A Ertuglu; Sepiso K Masenga; Annet Kirabo
Journal:  Curr Hypertens Rep       Date:  2022-02-05       Impact factor: 5.369

Review 3.  MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy.

Authors:  Ruxandra Florentina Ionescu; Sanda Maria Cretoiu
Journal:  J Med Life       Date:  2021 Mar-Apr

4.  MicroRNAs as the Potential Regulators of SARS-CoV-2 Infection and Modifiers of the COVID-19 Clinical Features.

Authors:  A N Kucher; Iu A Koroleva; A A Zarubin; M S Nazarenko
Journal:  Mol Biol       Date:  2022-02-12       Impact factor: 1.540

5.  miR-218 Involvement in Cardiomyocyte Hypertrophy Is Likely through Targeting REST.

Authors:  Jing-Jing Liu; Cui-Mei Zhao; Zhi-Gang Li; Yu-Mei Wang; Wei Miao; Xiu-Juan Wu; Wen-Jing Wang; Chang Liu; Duo Wang; Kang Wang; Li Li; Lu-Ying Peng
Journal:  Int J Mol Sci       Date:  2016-05-31       Impact factor: 5.923

6.  MicroRNA profiling identifies miR-7-5p and miR-26b-5p as differentially expressed in hypertensive patients with left ventricular hypertrophy.

Authors:  C M Kaneto; J S Nascimento; M C R Moreira; N D Ludovico; A P Santana; R A A Silva; I Silva-Jardim; J L Santos; S M B Sousa; P S P Lima
Journal:  Braz J Med Biol Res       Date:  2017-10-19       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.